These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37925965)

  • 1. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
    Wang Y; Broeks A; Giardiello D; Hauptmann M; Jóźwiak K; Koop EA; Opdam M; Siesling S; Sonke GS; Stathonikos N; Ter Hoeve ND; van der Wall E; van Deurzen CHM; van Diest PJ; Voogd AC; Vreuls W; Linn SC; Dackus GMHE; Schmidt MK
    Eur J Cancer; 2023 Dec; 195():113401. PubMed ID: 37925965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
    van Maaren MC; van Steenbeek CD; Pharoah PDP; Witteveen A; Sonke GS; Strobbe LJA; Poortmans PMP; Siesling S
    Eur J Cancer; 2017 Nov; 86():364-372. PubMed ID: 29100191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Prognostic App (iCanPredict) to Predict Survival for Chinese Women With Breast Cancer: Retrospective Study.
    Ma Z; Huang S; Wu X; Huang Y; Chan SW; Lin Y; Zheng X; Zhu J
    J Med Internet Res; 2022 Mar; 24(3):e35768. PubMed ID: 35262503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.
    Candido Dos Reis FJ; Wishart GC; Dicks EM; Greenberg D; Rashbass J; Schmidt MK; van den Broek AJ; Ellis IO; Green A; Rakha E; Maishman T; Eccles DM; Pharoah PDP
    Breast Cancer Res; 2017 May; 19(1):58. PubMed ID: 28532503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of adjuvant chemotherapy on survival of women with T1N0M0, hormone receptor negative breast cancer.
    Bhoo-Pathy NT; Inaida S; Tanaka S; Taib NA; Yip CH; Saad M; Kawakami K; Bhoo-Pathy N
    Cancer Epidemiol; 2017 Jun; 48():56-61. PubMed ID: 28371729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and External Validation of Prediction Models for 10-Year Survival of Invasive Breast Cancer. Comparison with PREDICT and CancerMath.
    Karapanagiotis S; Pharoah PDP; Jackson CH; Newcombe PJ
    Clin Cancer Res; 2018 May; 24(9):2110-2115. PubMed ID: 29444929
    [No Abstract]   [Full Text] [Related]  

  • 13. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
    Engelhardt EG; van den Broek AJ; Linn SC; Wishart GC; Rutgers EJT; van de Velde AO; Smit VTHBM; Voogd AC; Siesling S; Brinkhuis M; Seynaeve C; Westenend PJ; Stiggelbout AM; Tollenaar RAEM; van Leeuwen FE; van 't Veer LJ; Ravdin PM; Pharaoh PDP; Schmidt MK
    Eur J Cancer; 2017 Jun; 78():37-44. PubMed ID: 28412587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Predict, a prognostic risk tool, after diagnosis of a second breast cancer.
    Deng Z; Jones MR; Wolff AC; Visvanathan K
    JNCI Cancer Spectr; 2023 Oct; 7(6):. PubMed ID: 37773987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
    Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
    Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the online PREDICT tool in a cohort of early breast cancer in Brazil.
    Magário MB; Santos RRD; Teixeira LA; Tiezzi DG; Pimentel FF; Carrara HHA; Andrade JM; Reis FJCD
    Braz J Med Biol Res; 2022; 55():e12109. PubMed ID: 36350970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
    Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
    Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
    Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
    Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of young age on outcome in early stage breast cancer.
    Fowble BL; Schultz DJ; Overmoyer B; Solin LJ; Fox K; Jardines L; Orel S; Glick JH
    Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):23-33. PubMed ID: 8083119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.